Company news
Benitec Biopharma Inc. news in 2023
Benitec Biopharma Inc.'s news releases, calls and decks from 2023, newest first.
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
November 29, 2023
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
November 16, 2023
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
November 12, 2023
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
September 20, 2023
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
August 10, 2023
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
August 7, 2023
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
July 24, 2023
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
June 25, 2023
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update
May 14, 2023
Benitec Biopharma to Present at the OPMD International Conference
May 7, 2023
Benitec Biopharma to Present at the JMP Securities Life Sciences Conference
May 7, 2023
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
February 12, 2023
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
January 22, 2023
Decks in 2023
- Investor Presentation (July 2023)
Investor deck · 28 slides · July 2023
- Investor Presentation (January 2023)
Investor deck · 28 slides · January 2023